Evidence map›Paper›PMID 37314748›Full record

ArticleMolecular cancer research : MCR2023

Chromatin-Associated SIN3B Protects Cancer Cells from Genotoxic Stress-Induced Apoptosis and Dictates DNA Damage Repair Pathway Choice.

Jorge Morales-Valencia, Coralie Petit, Alexander Calderon, Siddharth Saini, Gregory David

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jorge Morales-ValenciaDepartment of Biochemistry and Molecular Pharmacology, NYU Langone Medical Center, New York, New York.ORCID 0009-0006-0405-9458
Coralie PetitDepartment of Biochemistry and Molecular Pharmacology, NYU Langone Medical Center, New York, New York.ORCID 0000-0001-5346-7171
Alexander CalderonDepartment of Biochemistry and Molecular Pharmacology, NYU Langone Medical Center, New York, New York.ORCID 0000-0002-7134-6282
Siddharth SainiDepartment of Biochemistry and Molecular Pharmacology, NYU Langone Medical Center, New York, New York.ORCID 0000-0002-2813-9536
Gregory DavidDepartment of Biochemistry and Molecular Pharmacology, NYU Langone Medical Center, New York, New York.ORCID 0000-0002-3371-4558
NYU Langone Health · US

Funding

Probing the coordination of cell cycle progression and differentiation in hematopoietic stem cellsR56HL163940 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DAVID, GREGORY · 2022 to 2022
$539k
Targeting the senescence-associated secretory phenotype as an adjuvant therapy to prevent breast cancer progressionR21CA246416 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DAVID, GREGORY · 2020 to 2020
$436k
NCI NIH HHS R21 CA246416NHLBI NIH HHS R56 HL163940
6 · The paper itself

Abstract

Transcription and DNA damage repair act in a coordinated manner. The scaffolding protein SIN3B serves as a transcriptional co-repressor of hundreds of cell cycle-related genes. However, the contribution of SIN3B during the DNA damage response remains unknown. Here, we show that SIN3B inactivation delays the resolution of DNA double-strand breaks and sensitizes cancer cells to DNA-damaging agents, including the chemotherapeutic drugs cisplatin and doxorubicin. Mechanistically, SIN3B is rapidly recruited to DNA damage sites where it directs the accumulation of Mediator of DNA Damage Checkpoint 1 (MDC1). In addition, we show that SIN3B inactivation favors the engagement of the alternative nonhomologous end joining (NHEJ) repair pathway over the canonical NHEJ. Altogether, our findings impute an unexpected function for the transcriptional co-repressor SIN3B as a gatekeeper of genomic integrity and a determining factor in the DNA repair choice pathway, and point to the inhibition of the SIN3B chromatin-modifying complex as a novel therapeutic vulnerability in cancer cells. IMPLICATIONS: Identifying SIN3B as a modulator of DNA damage repair choice provides novel potential therapeutic avenues to sensitize cancer cells to cytotoxic therapies.

Indexed as

ChromatinNeoplasmsApoptosisCo-Repressor ProteinsDNADNA DamageDNA End-Joining RepairDNA RepairHumansRepressor ProteinsChromatinCo-Repressor ProteinsDNARepressor ProteinsSIN3B protein, human

Identifiers

PMID37314748
PMCPMC10527583
OpenAlexW4380577721

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.